Immunotherapy in NSCLC Without Driver Alterations
For patients with NSCLC lacking actionable driver mutations, first-line immunotherapy selection depends critically on PD-L1 expression level and performance status, with pembrolizumab monotherapy recommended for PD-L1 ≥50% and immunotherapy-chemotherapy combinations for lower PD-L1 expression.
PD-L1 ≥50% (High Expression)
Single-agent pembrolizumab is the preferred first-line option for patients with PS 0-1, regardless of histology 1. This recommendation is based on superior survival outcomes with pembrolizumab monotherapy versus chemotherapy, demonstrating median PFS of 10.3 versus 6.0 months and 6-month OS of 80.2% versus 72.4% 2.
Alternative considerations:
- Pembrolizumab plus chemotherapy (pemetrexed/carboplatin for non-squamous; paclitaxel or nab-paclitaxel/carboplatin for squamous) can be appropriate in specific cases where more aggressive disease control is needed 2
- The survival benefit of adding chemotherapy to pembrolizumab in this high PD-L1 group remains unclear and may be diminished 1
PD-L1 1-49% (Low Positive Expression)
For non-squamous histology: Pembrolizumab plus pemetrexed and carboplatin is the standard recommendation 1. Alternative options include:
- Atezolizumab/bevacizumab/carboplatin/paclitaxel 1
- Atezolizumab/carboplatin/nab-paclitaxel 1
- Single-agent pembrolizumab may be considered in select cases 3
For squamous histology: Pembrolizumab plus carboplatin and (paclitaxel or nab-paclitaxel) is recommended 1. Atezolizumab/carboplatin/nab-paclitaxel represents an alternative option 1.
PD-L1 <1% (Negative Expression)
For non-squamous histology: Pembrolizumab/pemetrexed/carboplatin remains the preferred regimen 2, 1. The survival benefit for pembrolizumab-combination therapy is observed across all PD-L1 categories but is diminished in PD-L1-negative patients 1.
For squamous histology: Pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) is recommended 1.
Important caveat: Patients with PD-L1 <1% have notably worse outcomes, with median OS of 13.8 months compared to 18.4 months for PD-L1 ≥50% 4. This subgroup, particularly when combined with KRAS mutations, represents a high unmet need population 4.
Special Populations
High tumor mutational burden (TMB): Nivolumab plus ipilimumab represents a treatment option for PS 0-1 patients with high TMB, regardless of PD-L1 expression 1. However, recent head-to-head data from NIPPON/JCOG2007 showed no statistically significant OS difference between nivolumab/ipilimumab/chemotherapy versus pembrolizumab/chemotherapy (23.7 vs 20.5 months, p=0.46), with higher treatment-related deaths (7% vs 2%) and worse quality of life in the nivolumab/ipilimumab arm 5.
Performance status 2: Carboplatin-based combination therapy should be considered in eligible PS 2 patients, as chemotherapy prolongs survival and improves quality of life versus best supportive care 1. Single-agent chemotherapy (gemcitabine, vinorelbine, docetaxel, or pemetrexed for non-squamous) is an alternative 1.
Performance status 3-4: Best supportive care only, unless a molecularly targetable alteration with minimal toxicity therapy is identified 1.
Elderly patients (≥70 years): Immunotherapy should be considered according to standard recommendations 1. Carboplatin-based doublet chemotherapy is appropriate for PS 0-2 with adequate organ function 1.
Critical Testing Requirements
All patients must undergo:
- PD-L1 testing at diagnosis (unanimously recommended) 2, 1
- Comprehensive molecular testing to exclude EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK, and KRAS G12C alterations 1
Common Pitfalls
Avoid immunotherapy in patients with:
- Active or previously documented autoimmune disease requiring immunosuppression 6
- Certain oncogenic drivers (EGFR exon 19 deletion/L858R, ALK, RET, ROS1 rearrangements) show reduced benefit from PD-1/PD-L1 inhibitors 7, 6
Treatment duration: Continue until progression, unacceptable toxicity, or response completion 2. Maintenance therapy in combination regimens should follow protocol-specific guidelines (typically up to 2 years for pembrolizumab) 5.
Smoking history: While 71% of experts felt PD-L1 expression was predictive of checkpoint inhibitor response, 29% also considered smoking history predictive 2.